Drug Combination Details
| General Information of the Combination (ID: C21207) | |||||
|---|---|---|---|---|---|
| Name | Cyclopamine NP Info | + | Gemcitabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | SW1990 | CVCL_1723 | Pancreatic adenocarcinoma | Homo sapiens | ||
| CFPAC-1 | CVCL_1119 | Cystic fibrosis | Homo sapiens | |||
| Experimental
Result(s) |
Gemcitabine-resistant pancreatic cancer cells highly express CSCs markers and some of the HH members, and inhibition of HH by cyclopamine is an effective method of reversing gemcitabine resistance in pancreatic cancer. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines. Swiss Med Wkly. 2011 May 31;141:w13208. | |||
